Enveric Biosciences Inc
ENVB
Get informed when a big investor buys or sells
+ FollowMarket Cap$764.18K
Close$
$13.97
935.1% upside
Current Fair Value
935.1% upsideUndervalued by 935.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $764,175.00 |
|---|---|
| Enterprise Value | $-4,144,594.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-36.24 |
| Beta | 1.1 |
| Outstanding Shares | 1,510,401 |
Return
| Return on Equity | -192.34% |
|---|---|
| Return on Assets | -176.29% |
| Return on Invested Capital | -162.42% |
Valuation & Multiples
| P/E Ratio | -0.05 |
|---|---|
| PEG | 0.19 |
| Price to Sales | - |
| Price to Book Ratio | 0.45 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.5 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 19, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 17, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.64%▲ 1.36% |
|---|---|
| Total Invested | $106,594▲ 21.48% |
| Investors Holding | 110% |
ESG Score
No data
About Enveric Biosciences Inc
3 employees
CEO: Brent Kelton Enveric Biosciences is a patient-first biotechnology company developing rigorously tested, novel cannabinoid medicines to improve quality of life for cancer patients. Initial indications include radiodermatitis, a common and often severe...